About the Psoriatic Arthritis Working Group
Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease occurring in 7–42% of patients with psoriasis. Arthritis, enthesitis, dactylitis, spondylitis, and skin disease result in pain, stiffness, reduced mobility, impairment in physical function, and subsequent disability. PsA is now recognized as a disease that can be serious and progressive despite treatment, resulting in significant physical, psychological, functional, and social impairment.
The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set
Dafna Gladman
Co-Chair
Katy Leung
Co-Chair
Ana-Maria Orbai
Co-Chair
William Tillett
Co-Chair
Niti Goel
Patient Research Partner
OMERACT Endorsed Core Domain Set for Psoriatic Arthritis
OMERACT INSTRUMENT SELECTION CERTIFICATES
RECENT WORKING GROUP PUBLICATIONS
Measurement Properties of Radiographic Outcome Measures in Psoriatic Arthritis: A Systematic Review from the GRAPPA-OMERACT Initiative
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016